


This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Original): A method for treating a symptom of MCI comprising administering to a mammal in need of such therapy, an effective amount of a compound of formula (I)



2. (Original): The method of claim 1 wherein the symptom of MCI is an impairment of memory function compared to one's age cohort; memory impairment that is at least one standard deviation below that of a subject's peers, but without significant impairment in activities of daily living; reduced medial lobe volume; delayed recall tasks or verbal and nonverbal stimuli; a decline in linguistic function or verbal fluency; or impairment in a single cognitive domain other than memory.

3. (Original): The method of claim 1 wherein the symptom of MCI is the progression from MCI to AD.

4. (Original): The method of claim 1 wherein the symptom of MCI is a symptom other than the progression from MCI to AD.

5. (Original): The method of claim 3 wherein the rate of progression from MCI to AD is reduced by at least about 10 percent.

6. (Original): The method of claim 3 wherein the rate of progression from MCI to AD is reduced by at least about 20 percent.

7. (Original): The method of claim 3 wherein the rate of progression from MCI to AD is reduced by at least about 50 percent.

8. (Amended): The method of ~~any one of claims 1-7~~ claim 1 wherein the compound is  $\text{C}_6\text{H}_5\text{CH}_2\text{-C(=O)-L-Pro-Gly-OC}_2\text{H}_5$ , or a pharmaceutically acceptable salt thereof.

Claims 9-16 are cancelled.